Skip to main content
. 2024 Aug;86(3):452–463. doi: 10.18999/nagjms.86.3.452

Fig. 2.

Fig. 2

Overall survival (OS) in patients with and without anti-thyroid antibodies (ATAs) at baseline

Solid and dashed lines indicate the OS of patients who did and did not have ATAs at baseline, respectively.

Fig. 2A: OS in patients with ≥50% PD-L1 positivity.

Fig. 2B: OS in patients with <50% PD-L1 positivity.